{"id":"W2478932238","doi":"10.1182/blood-2016-03-707596","title":"Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Onyx Pharmaceuticals; Agence Nationale de la Recherche; National Cancer Institute; Celgene; Amgen","keywords":"Carfilzomib; Multiple myeloma; Internal medicine; Oncology; Medicine; Overall survival; Progression-free survival; Cytogenetics; Lenalidomide; Biology; Genetics; Chromosome","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002857387,0.000171947,0.0003253024,0.000106023,0.0000731191,0.000009217794,0.0002619737,0.00008131791,0.00004462595],"category_scores_gemma":[0.001646013,0.00007760259,0.00009360148,0.0001984209,0.0001721142,0.00006835987,0.0001572991,0.0001402117,0.00002923825],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002875359,"about_ca_system_score_gemma":0.0001066119,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001050663,"about_ca_topic_score_gemma":0.0006271407,"domain_scores_codex":[0.998175,0.0001608472,0.0003347894,0.0003018486,0.0006214814,0.0004060392],"domain_scores_gemma":[0.9983003,0.0005282951,0.0001476341,0.0006981998,0.0001614553,0.0001640783],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006149632,0.001872203,0.9124592,0.0000383928,0.0001646692,0.00004045088,0.0001062518,9.527691e-8,0.01220308,0.0000322274,0.00008460771,0.07238385],"study_design_scores_gemma":[0.02643988,0.0008350542,0.9208813,0.0001521666,0.00008161116,0.000002232769,0.00005380189,0.000009754657,0.05124272,0.0001303636,0.00008229672,0.00008877437],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978659,0.0001228697,0.000007352875,0.0003278938,0.00009418652,0.001030399,0.0002284786,0.00002983358,0.0002930957],"genre_scores_gemma":[0.9989201,0.0001115416,0.0005128117,0.00001227774,0.00007393374,0.0001217813,0.00002598445,0.00002553224,0.0001960347],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07229508,"threshold_uncertainty_score":0.3164542,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01630979111809902,"score_gpt":0.2668410858789262,"score_spread":0.2505312947608273,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}